Pacific Biosciences of California (PACB) Projected to Post Earnings on Wednesday

Pacific Biosciences of California (NASDAQ:PACB) is anticipated to release its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Pacific Biosciences of California to post earnings of ($0.16) per share and revenue of $40.2460 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Wednesday, March 29th. The biotechnology company reported ($0.23) EPS for the quarter. Pacific Biosciences of California had a negative net margin of 336.40% and a negative return on equity of 66.75%. The business had revenue of $3.34 million during the quarter. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pacific Biosciences of California Stock Down 4.3%

PACB opened at $2.24 on Tuesday. Pacific Biosciences of California has a 12 month low of $0.85 and a 12 month high of $2.72. The company has a debt-to-equity ratio of 10.51, a current ratio of 6.92 and a quick ratio of 6.02. The stock has a market cap of $672.83 million, a P/E ratio of -0.98 and a beta of 2.10. The stock’s 50 day moving average price is $1.50 and its 200 day moving average price is $1.34.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PACB shares. Piper Sandler lifted their price target on Pacific Biosciences of California from $1.25 to $1.50 and gave the company a “neutral” rating in a research report on Monday, August 11th. Wall Street Zen upgraded Pacific Biosciences of California from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pacific Biosciences of California presently has a consensus rating of “Hold” and an average price target of $1.90.

Hedge Funds Weigh In On Pacific Biosciences of California

Hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. grew its holdings in shares of Pacific Biosciences of California by 73.0% in the 2nd quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 15,062 shares during the last quarter. HUB Investment Partners LLC acquired a new position in shares of Pacific Biosciences of California in the 2nd quarter worth $77,000. Canada Pension Plan Investment Board grew its holdings in shares of Pacific Biosciences of California by 1,027.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 73,300 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 66,800 shares during the last quarter. Engineers Gate Manager LP acquired a new position in shares of Pacific Biosciences of California in the 2nd quarter worth $110,000. Finally, Cetera Investment Advisers grew its holdings in shares of Pacific Biosciences of California by 10.1% in the 2nd quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 9,617 shares during the last quarter.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.